In 18 weeks, Medtronic has signed four deals worth a combined $2.47 billion. Three of those closes landed in the last 14 days. That kind of velocity is not opportunistic. It is a strategy. Meanwhile, Oura filed an S-1, signaling that the consumer-medtech boundary is officially dissolving. Welcome to Issue #25.
Top Stories
Story 01
Oura has submitted a draft registration statement on Form S-1 with the SEC, signaling that the smart ring maker is targeting a public listing at a valuation the company internally projects at $11 billion. The company generated roughly $250 million in 2024 revenue and is projecting nearly $2 billion in sales for 2026, a 4x jump over two fiscal years, driven by a constellation of health data partnerships with Dexcom, Vida Health, Midi Health, and Mira. (Source: MD+DI, May 22, 2026)
The smart ring market is projected to grow from $341 million in 2024 to over $2.5 billion by 2032 at a 29.3% CAGR. Oura has sold 5.5 million rings since 2015 and recently expanded into pregnancy, menopause, and lab-grade hormone tracking. All territories that blur the line between wellness and clinical. The Dexcom partnership puts real-time glucose data inside the ring ecosystem. The Midi Health and Mira integrations target women's health, a segment Oura describes as a path to capturing a share of the $60 billion femtech market.
Why It Matters
Oura is the first pure-play MedTech consumer wearable to file for a U.S. public listing at this valuation scale. Its trajectory, from sleep tracking to pregnancy support to metabolic health. Mirrors the broader shift from consumer wellness to structured clinical data. If the IPO succeeds at the projected valuation, it establishes a new benchmark for MedTech-adjacent consumer health companies seeking public markets. Every strategic partnership it signed in the past 12 months was designed to make that number achievable.
Builder's Note
The Dexcom integration is the canary in the coal mine. When a glucose monitoring company, a category with real regulatory history and clinical trust, decides Oura's ring is a credible distribution vehicle, the wellness/MedTech boundary officially collapses. Start paying attention to which MedTech companies are signing distribution deals with consumer wearables. That is where the next regulatory frontier lives.
IPO
Digital Health
Funding
Story 02
Medtronic has established a European Patient Care Systems software hub in Galway, Ireland, its existing cardiac R&D hub for 40 years. The new hub will develop cloud-based platforms and clinical software for connected care monitoring in patients with implanted cardiac devices. The investment adds 85 jobs initially, with more growth anticipated over three years. (Source: MedTech Dive, May 22, 2026)
Medtronic has invested roughly 11 billion euros in Ireland since 2015, when it re-domiciled to Dublin following the Covidien acquisition. The Galway hub expands on the company's existing footprint while building the software infrastructure to support its growing portfolio of connected cardiac devices. New roles include leadership, software engineering, and systems reliability positions.
Why It Matters
Medtronic has been building a hardware empire for 45 years. This hub signals the next phase. Software as a differentiator for hardware. Connected care monitoring platforms let Medtronic capture real-world device performance data, support clinical decision-making, and create switching costs that pure hardware competitors cannot match. The Ireland location gives access to EU digital health talent and positions the company closer to the EU AI Act compliance infrastructure it now needs to navigate.
Software
Cardiac
Digital Health
Story 03
Medtronic has agreed to acquire SPR Therapeutics for $650 million, adding the company's FDA-cleared SPRINT PNS System to its neuromodulation portfolio. The deal marks Medtronic's third acquisition announcement in five weeks and fourth in 18 weeks, following the $583 million CathWorks deal, the $585 million AI-powered coronary assessment acquisition, and a $100 million strategic investment in Pulnovo Medical's pulmonary artery denervation technology. (Source: Medtronic, May 20, 2026)
SPRINT PNS is a temporary, 60-day percutaneous peripheral nerve stimulation therapy that does not require a permanent implant. The device is designed for patients earlier in the chronic pain continuum. A strategic bridge between conservative management and permanent neurostimulation. The largest retrospective review of real-world PNS data, conducted across 6,100 patients using the SPRINT system, showed over 71% of participants achieved significant pain relief and/or improvement in quality of life. The deal is subject to regulatory approvals and expected to close in the first half of Medtronic's fiscal year 2027.
Why It Matters
Medtronic CEO Geoff Martha said at the start of 2026 that the company was going on offense with strategic M&A. Week 18 of that offense is a $650 million check for a device that treats pain without permanent hardware. A direct response to the clinical and commercial reality that early-intervention pain therapy is where the market is moving. The 6,100-patient real-world data package is the regulatory and commercial credential that makes this a buyable deal, not a speculative bet.
M&A
Neuromodulation
Pain
Story 04
Endologix has acquired the Pounce Thrombectomy System from Surmodics, closing the deal on May 18. Pounce is a fully mechanical, dual-basket catheter system for the non-surgical removal of thrombi and emboli from peripheral arteries. The platform includes three configurations: Pounce LP, Pounce, and Pounce XL. Covering a range of peripheral arterial vessel sizes. (Source: Endologix, May 20, 2026)
Pounce uses proprietary dual-basket technology and a nitinol collection funnel designed to push clots into the funnel as baskets are withdrawn. A mechanical approach that requires no thrombolytics, no capital equipment, and no aspiration system. Surmodics began commercializing Pounce in 2022 and generated "modest but meaningful and growing revenue" from the platform. Surmodics was acquired by GTCR for $627 million last year after defeating an FTC challenge, and the Pounce divestiture is part of its portfolio simplification under private equity ownership.
Why It Matters
The peripheral vascular intervention space is becoming one of MedTech's most active battlegrounds. Endologix already has the ALTO and AFX2 aortic systems and the Detour procedure for PAD; adding a mechanical thrombectomy platform lets it serve the same physicians across a broader patient spectrum. The move also illustrates how PE ownership changes acquisition behavior. GTCR bought Surmodics, pruned the non-core asset, and Endologix picked up a proven platform at undisclosed terms. PE logic creates MedTech opportunity.
M&A
Vascular
Peripheral
Story 05
Two analyses from Medtronic's global SYMPLICITY registry, presented as abstracts at the EuroPCR meeting in Paris, showed sustained and significant blood pressure reductions three years after renal denervation using Medtronic's Symplicity Spyral system. In 903 patients with severe hypertension, office systolic blood pressure dropped 40 mmHg at three years, compared to baseline, and the number of antihypertensive medications did not increase over that period. (Source: MedTech Dive, May 20, 2026)
In a separate cohort of 787 patients with prior cardiovascular events, renal denervation produced a 17.4 mmHg reduction in office systolic blood pressure and a 9.9 mmHg reduction in 24-hour ambulatory BP at three years. Adverse event rates across both cohorts were low. No safety events related to the procedure itself. CMS issued a national coverage determination for renal denervation last year, removing a major reimbursement barrier for Medtronic's growth thesis.
Why It Matters
Three-year data in a large registry is the kind of evidence that turns a clinical concept into a standard of care. The severe hypertension cohort's 40 mmHg sustained reduction is not a marginal result. It is a clinical signal that renal denervation can function as a durable standalone therapy for the hardest-to-treat patients. With CMS coverage now active, this data gives Medtronic the post-market evidence package needed to drive physician adoption and defend the Symplicity franchise against Recor Medical's Paradise system.
Clinical Data
Cardiac
CMS Policy
Industry Shift
The consolidation pattern this week is not random. Medtronic's $2.47 billion, four-deal sprint since February signals a deliberate repositioning around three growth vectors: AI-guided coronary physiology (CathWorks), connected cardiac software infrastructure (Ireland hub), and pain intervention earlier in the care continuum (SPR Therapeutics). The common thread is not product category. It is data capture and physician workflow integration. Each deal adds a data source or a software layer that makes Medtronic's existing hardware portfolio more defensible. That is a PE-grade M&A logic applied inside a public MedTech company, and it is working: MDT has not issued guidance cut warnings since Q3 2025.
Oura's S-1 filing introduces a second structural shift: the consumer-medtech border is officially dissolving. When Dexcom, a company with 510(k) and PMA clearances, real clinical evidence, and payer relationships, signs a distribution deal with a consumer ring company, the regulatory wall between wellness and clinical is not just cracking. It is being renegotiated by the companies on both sides.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $463.50 | ▲ 0.3% |
| SYK | Stryker | $301.40 | ▲ 0.4% |
| BDX | Becton Dickinson | $236.20 | ▲ 0.2% |
| JNJ | Johnson & Johnson | $226.10 | ▲ 0.3% |
| ABT | Abbott Laboratories | $112.40 | ▲ 0.5% |
| ZBH | Zimmer Biomet | $98.30 | ▲ 0.3% |
| EW | Edwards Lifesciences | $86.80 | ▼ 0.4% |
| MDT ★ | Medtronic | $84.20 | ▲ 2.1% |
| BSX | Boston Scientific | $78.90 | ▲ 0.6% |
| GEHC | GE HealthCare | $64.20 | ▲ 0.6% |
★ Biggest Mover: Medtronic (MDT) rose 2.1% following the announcement of the SPR Therapeutics $650M acquisition and the European software hub opening in Ireland. Back-to-back deal announcements in the same week signal operational execution confidence. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of May 19–23, 2026. For illustrative purposes only.
⏳ That’s your 5-minute briefing. Below: extras if you want to go deeper.
Fun Fact
💡 Fun Fact — Medtronic's Ireland Footprint
Medtronic has invested approximately 11 billion euros in Ireland since 2015, when it relocated its principal executive office to Dublin following the Covidien acquisition. The company's Galway site. Now expanding with a new European Patient Care Systems software hub. It has been Medtronic's primary cardiac R&D hub in the country for four decades.
Trivia
MedTech Trivia
In the SYMPLICITY registry analysis of patients with severe hypertension, what was the sustained office systolic blood pressure reduction at three years post-renal denervation, and how did the number of antihypertensive medications compare to baseline?
If you’re building, hiring, or investing in MedTech, reply and tell me what you’re seeing. I read every response.
